Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Pereira Brian JG
   2. Issuer Name and Ticker or Trading Symbol
AMAG PHARMACEUTICALS INC. [AMAG] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President and CEO
(Last)
(First)
(Middle)
C/O AMAG PHARMACEUTICALS, INC., 100 HAYDEN AVENUE		 3. Date of Earliest Transaction (Month/Day/Year)
11/09/2009
(Street)

LEXINGTON, MA 02421		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/09/2009   M   55,300 A $ 9.1 88,267 D  
Common Stock 11/09/2009   S   55,300 D $ 44.254 (1) 32,967 D  
Common Stock 11/09/2009   M   50,744 A $ 9.1 83,711 D  
Common Stock 11/09/2009   S   50,744 D $ 43.476 (2) 32,967 D  
Common Stock 11/09/2009   S   32,967 D $ 44.823 (3) 0 I (4) By self as Trustee
Common Stock 11/09/2009   M   8,000 A $ 8.98 8,000 D  
Common Stock 11/09/2009   S   8,000 D $ 43.347 (5) 0 D  
Common Stock 11/10/2009   M   15,000 A $ 13.45 15,000 D  
Common Stock 11/10/2009   S   15,000 D $ 43.39 (6) 0 D  
Common Stock 11/10/2009   M   8,000 A $ 13.55 8,000 D  
Common Stock 11/10/2009   S   8,000 D $ 43.149 (7) 0 D  
Common Stock 11/10/2009   M   60,000 A $ 10.8 60,000 D  
Common Stock 11/10/2009   S   60,000 D $ 43.195 (8) 0 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Options (Right to Buy) $ 9.1 11/09/2009   M     55,300   (9) 11/16/2015 Common 55,300 $ 0 50,744 D  
Employee Stock Options (Right to Buy) $ 9.1 11/09/2009   M     50,744   (9) 11/16/2015 Common 50,744 $ 0 0 D  
Employee Stock Options (Right to Buy) $ 8.98 11/09/2009   M     8,000   (9) 11/01/2015 Common 8,000 $ 0 0 D  
Employee Stock Options (Right to Buy) $ 13.45 11/10/2009   M     15,000   (9) 07/26/2014 Common 15,000 $ 0 0 D  
Employee Stock Options (Right to Buy) $ 13.55 11/10/2009   M     8,000   (9) 11/02/2014 Common 8,000 $ 0 0 D  
Employee Stock Option (Right to Buy) $ 10.8 11/10/2009   M     60,000   (9) 07/12/2015 Common 60,000 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Pereira Brian JG
C/O AMAG PHARMACEUTICALS, INC.
100 HAYDEN AVENUE
LEXINGTON, MA 02421		   X     President and CEO  

Signatures

 Joseph L. Farmer, attorney-in-fact   11/12/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold in this transaction. The actual sales prices range from $44.625-$43.640. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
(2) The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold in this transaction. The actual sales prices range from $43.62-$43.10. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
(3) The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold in this transaction. The actual sales prices range from $44.60-$45.09. Upon request of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
(4) 12,211 of these shares were held in The Brian J.G. Pereira 2004 Trust, and 20,756 of the shares were held in the Brian Pereira Grantor Retained Annuity Trust. Dr. Pereira is the Trustee of both trusts.
(5) The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold in this transaction. The actual sales prices range from $43.57-$43.14. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
(6) The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold in this transaction. The actual sales prices range from $43.51-$43.17. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
(7) The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold in this transaction. The actual sales prices range from $43.24-$43.00. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
(8) The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold in this transaction. The actual sales prices range from $43.95-$43.00. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
(9) Not applicable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.